A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary)
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 01 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 01 Apr 2019 Planned primary completion date changed from 1 Mar 2019 to 31 Mar 2021.
- 04 Dec 2018 Results (n=17, data cut off: Jul 2018) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology